🏭
For employers
A scoped onsite programme, defined responsibilities, minimal operational disruption and an aggregate, de-identified outcome report.
Pre-pilot stage · India
Vision care where people work and learn.
neevan is an early-stage initiative developing an institution-led vision-screening and care-coordination service for workplaces in India. Our proposed pilot model is intended to combine established portable technology, qualified eye-care professionals, referral and eyewear pathways, and outcome-focused reporting.
neevan is currently validating its operating model and partnerships. We do not claim proprietary diagnostic hardware, proprietary clinical AI, autonomous diagnosis, or guaranteed clinical or economic outcomes.
The first product
neevan Workplace Vision Pilot
One site. One defined workforce. One workflow approved with clinical partners before deployment. One completion report.
- 1Reach
Scheduled onsite access with minimal disruption. - 2Screen and review
Approved measurement workflow with qualified clinical oversight. - 3Connect and correct
Referral, prescription and optional eyewear coordination. - 4Follow up
Completion tracking and aggregate programme reporting.
Workplace-first validation
A complete pathway—not just an eye camp
The aim is to learn whether a safe, convenient screening-to-care programme can create value for employees and institutions at repeatable economics.
👁️
For employees
Convenient access, clear communication, qualified review and a supported pathway to appropriate correction or further care.
📋
For clinical partners
Defined clinical ownership, documented escalation, quality controls and no suggestion that screening replaces comprehensive eye examination.
Pilot scope may include
- ✓ Site assessment, scheduling and participant communication
- ✓ Appropriate notice/consent and minimum-necessary data capture
- ✓ Approved portable screening or assessment technology
- ✓ Qualified clinical review and escalation
- ✓ Referral and optional eyewear coordination
- ✓ Follow-up and aggregate outcome reporting
Not promised at this stage
- — Autonomous diagnosis or a comprehensive eye-health clearance
- — Proprietary neevan device or clinical algorithm
- — Guaranteed accuracy, screening time or delivery time
- — Guaranteed productivity improvement or financial ROI
- — Employer access to identifiable clinical results
- — Large fleets or nationwide deployment before validation
Clinical governance
Screen → Review → Connect → Correct → Follow up
The exact workflow, device scope, operator requirements and escalation rules will be approved with qualified India-based clinical and regulatory advisers before a public pilot.
01
Screen
Approved measurements within the selected device's intended use.
02
Review
Qualified clinical interpretation where the protocol requires it.
03
Connect
Clear routine, additional-assessment or urgent referral pathway.
04
Correct
Prescription and eyewear only through appropriately authorized partners.
05
Follow up
Completion tracking, exceptions and patient communication.
Important: a vision screen is not a comprehensive ophthalmic examination. A normal screening result cannot rule out every eye condition. Urgent symptoms or red flags must follow the approved clinical escalation pathway.
How we are building
Evidence before claims. Safety before scale.
neevan is deliberately starting with partners and a narrow service model. We will build proprietary software or technology only after real deployments show what is necessary and valuable.
Customers before technology
Prove demand and willingness to pay first.
Care completion over vanity metrics
Measure whether people reach correction or referral.
Privacy by design
Minimize data and separate individual care from employer reporting.
Capital discipline
No fleet or custom platform before repeatability.
Our validation sequence
- 1. Partner readiness
Technology, clinical, referral and optical relationships. - 2. Safe operating design
Intended use, SOPs, privacy, contracts and insurance. - 3. First paid pilot
One institution, defined cohort and pre-agreed success criteria. - 4. Repeat and measure
Operational quality, completion, contribution economics and renewal. - 5. Scale selectively
Only when evidence supports people, nodes and software.
Evidence used responsibly
Why workplace vision deserves testing
Research shows that correcting vision can improve work outcomes in specific populations. For example, the PROSPER randomized trial studied near-vision glasses among tea workers aged 40 and older in Assam. That result supports the importance of workplace access—but it does not prove the same effect for every occupation, workforce or neevan pilot.
neevan will not promise productivity gains. Where appropriate and agreed with customers, pilots may measure relevant operational or experience outcomes using defensible baselines.
Read the PROSPER study →Questions
Frequently asked questions
Does neevan have its own diagnostic AI or medical device?+
No. neevan is currently designing a service using established third-party technology. The exact device and software combination will be selected only after commercial, clinical and regulatory diligence.
Does screening replace an eye examination?+
No. Screening identifies people who may benefit from correction or further assessment. The final protocol will distinguish measurement, screening, clinical interpretation, prescription, referral and treatment.
Which technology will the pilot use?+
neevan is evaluating established portable vision-screening and assessment technologies. The final device and software configuration will be selected only after commercial, clinical, regulatory, data-security and workflow diligence has been completed.
How quickly will glasses be delivered?+
Turnaround will depend on prescription complexity, the contracted optical partner, quality checks and site logistics. A service level will be offered only after partner capability has been verified.
What information does an employer receive?+
The default model is aggregate, de-identified programme reporting. Individual clinical information should not be shared with an employer unless a specific lawful and ethical basis applies.
Is the first pilot free?+
neevan is seeking paid or sponsored pilots. Scope and pricing will be based on the site, population, selected technology, clinical requirements, travel and fulfilment model.
Pilot conversations are open
Help shape the first neevan workplace pilot.
We want to speak with Indian employers, occupational-health teams, qualified eye-care professionals, technology partners and optical fulfilment providers. An enquiry starts a discovery conversation—it is not a promise of immediate deployment.
✓ Manufacturing and industrial sites
✓ HR, EHS and occupational-health leaders
✓ Optometrists and ophthalmologists
✓ Portable vision-technology and optical partners
Privacy notice
Contact enquiries
neevan is currently an early-stage initiative and is not yet an incorporated Indian legal entity. Until an operating entity is formed, this website and its enquiries are managed by the founder of the neevan initiative.
When you submit the pilot-enquiry form, the founder receives the name or institution, work email, enquiry role, location and message that you provide. This information is used only to review and respond to your enquiry and to manage any resulting business conversation.
The form is transmitted through Web3Forms, a third-party form-delivery provider. Please do not submit patient records, medical information or other sensitive personal data. We keep enquiry information only for as long as reasonably necessary for the conversation, related business records and applicable legal obligations.
You may ask to access, correct or delete your enquiry information, or withdraw your consent, by using the form and beginning your message with “Privacy request”. Withdrawing consent does not affect processing already completed before the request.
This notice applies to website enquiries only. Any future pilot involving participant or clinical information will require a separate, approved privacy and consent process before deployment.